Show simple item record

dc.contributor.authorXu, Wen Wen
dc.contributor.authorBin, Li
dc.contributor.authorLam, Alfred Ky
dc.contributor.authorTsao, Sai Wah
dc.contributor.authorLaw, Simon YK
dc.contributor.authorChan, Kwok Wah
dc.contributor.authorYuan, Qiu Ju
dc.contributor.authorCheung, Annie LM
dc.date.accessioned2017-08-14T22:05:27Z
dc.date.available2017-08-14T22:05:27Z
dc.date.issued2015
dc.identifier.issn1949-2553
dc.identifier.doi10.18632/oncotarget.2781
dc.identifier.urihttp://hdl.handle.net/10072/141917
dc.description.abstractIncreasing appreciation of tumor heterogeneity and the tumor-host interaction has stimulated interest in developing novel therapies that target both tumor cells and tumor microenvironment. Bone marrow derived cells (BMDCs) constitute important components of the tumor microenvironment. In this study, we aim to investigate the significance of VEGFR1- and VEGFR2-expressing non-tumor cells, including BMDCs, in esophageal cancer (EC) progression and in VEGFR1/VEGFR2-targeted therapies. Here we report that VEGFR1 or VEGFR2 blockade can significantly attenuate VEGF-induced Src and Erk signaling, as well as the proliferation and migration of VEGFR1+ and VEGFR2+ bone marrow cells and their pro-invasive effect on cancer cells. Importantly, our in vivo data show for the first time that systemic blockade of VEGFR1+ or VEGFR2+ non-tumor cells with neutralizing antibodies is sufficient to significantly suppress esophageal tumor growth, angiogenesis and metastasis in mice. Moreover, our tissue microarray study of human EC clinical specimens showed the clinicopathological significance of VEGFR1 and VEGFR2 in EC, which suggest that anti-VEGFR1/VEGFR2 therapies may be particularly beneficial for patients with aggressive EC. In conclusion, this study demonstrates the important contributions of VEGFR1+ and VEGFR2+ non-tumor cells in esophageal cancer progression, and substantiates the validity of these receptors as therapeutic targets for this deadly disease.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherImpact Journals LLC
dc.relation.ispartofpagefrom1790
dc.relation.ispartofpageto1805
dc.relation.ispartofissue3
dc.relation.ispartofjournalOncotarget
dc.relation.ispartofvolume6
dc.subject.fieldofresearchClinical Sciences not elsewhere classified
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode110399
dc.subject.fieldofresearchcode1112
dc.titleTargeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/3.0/
gro.rights.copyright© The Author(s) 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorLam, Alfred K.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record